Pharmanutra S.p.a. · MIL:PHN
Pharmanutra — Investor Day (February 2023)
23 slides from Pharmanutra's investor day presentation, Feb 21, 2023
Slide 1: Pharmanutra 2030 Investor Day
PHARMANUTRA 2030 INVESTOR DAY February 21th, 2023
Slide 2: Disclaimer
2 DISCLAIMER This document has been prepared by Pharmanutra S.p.A. (the “Company”) for use during meetings with investors and financial analyst and is solely for information purposes. It contains solely data and information provided by the Company or already in the public domain. This Document may n
Slide 3: Growth Boosters
3 GROWTH BOOSTERS THE NEW GROWTH DRIVERS FOR THE NEXT 5 TO 10 YEARS THE RIGHT MOMENTUM TO INVEST IN LONG TERM BUSINESS OPPORTUNITIES Financial strenght - positive cash position Solid double-digit organic growth trend in terms of sales and profitability Significant potential market opportunies to exp
Slide 4: Group Presentation
GROUP PRESENTATION @PHARMANUTRA
Slide 5: Pharmanutra Group
5 PHARMANUTRA 2022 GROUP Research and development of bioimpedance medical devices and software for body composition analysis PharmaNutra holds 100% of 2010 Junia Pharma, Alesco and Akern. Medical products and devices, OTC and dietary Just three years after the listing supplements for children on the
Slide 6: Pharmanutra's Uniqueness: Intellectual Property Protection
6 PHARMANUTRA’S UNIQUENESS Intellectual Property Protection 01 02 03 04 No player in the dietary supplements and medical devices industry has these 18 19 39 151 PROPRIETARY PATENTS BASED REGISTERED RESEARCH 4 STRONG PILLARS IN RAW MATERIALS ON PURE INNOVATION BRANDS STUDIES ONE SINGLE COMPANY PROPRI
Slide 7: Pharmanutra's Uniqueness: Time to Market
7 PHARMANUTRA’S UNIQUENESS Time to Market PRE-CLINICAL E CLINICAL STUDIES PATENT PROTECTION SALES & DISTRIBUTION
Slide 8: Economic and Financial Data
ee eee een SS ECONOMIC AND FINANCIAL DATA Q@PHARMANUTRA a ~~
Slide 9: Net Revenues
9 NET REVENUES Net Revenues (€ Million) Net Revenues by Business Line *2022 data NOT AUDITED yet
Slide 10: Net Revenues Growth
10 NET REVENUES GROWTH *2022 data NOT AUDITED yet
Slide 11: Net Financial Position
11 NET FINANCIAL POSITION 17,5 M€ CASH GENERATED FROM OPERATING ACTIVITIES *2022 data NOT AUDITED yet
Slide 12: Stock Performance 2018-2022
12 STOCK PERFORMANCE* 2018-2022 Pharmanutra 2018-2022 +391% FTSE IT STAR 2018-2022 +26% *Source: Investing.com
Slide 13: Growth Drivers to 2030
GROWTH DRIVERS TO 2030 @PHARMANUTRA
Slide 14: Akern
14 AKERN CLINICAL ENVIRONMENT EXPLOITING NEW TARGET Developing new clinical market Gaining benefit from Pharmanutra's segments thanks to the established network of partners Pharmanutra’s know-how SPORTS FIELD AND SPORTING EVENTS Strenghten the presence in sports field through the organization of joi
Slide 15: Cetilar Nutrition
15 CETILAR® NUTRITION COMMUNICATION INVESTMENTS Investments in tailored marketing & communication campaign, exploiting Cetilar strong franchise in sport B2B Creation of a specific sales network to INNOVATIVE PRODUCTS promote products to doctors, PORTFOLIO pharmacies, sport shops and professional spo
Slide 16: Pharmanutra España
16 PHARMANUTRA ESPAÑA CULTURAL AFFINITIES SYNERGIES WITH AKERN Culture, habits and lifestyle similar to Italy Opportunity to develop the domestic Spanish market in collaboration with Akern CROSS PRODUCT PORTFOLIO FINANCIAL EFFORT Sales & Distribution of Limited investments the full Cetilar brand req
Slide 17: Pharmanutra USA
17 PHARMANUTRA USA US MARKET POTENTIAL Developing Pharmanutra’s footprint in one of the most wealthy markets in the world NETWORK OF PARTNERS Strengthen and develop the relationships estabilished during scientific congresses and motorsport events PHARMANUTRA’S TOP BRAND AND PRODUCTS Entering in the
Slide 18: China
18 CHINA OTC MARKET POTENTIAL Online iron market estimated above 100 M€ per year with more than 40 M€ from foreign products. Yearly double-digit growth on the e-commerce channel expected in the next five years MARKETING B2C Flexible Cross-border sales marketing through the TMG strategies that store
Slide 19: Speed Up R&D & Innovation
19 SPEED UP R&D & INNOVATION NEW LABORATORY The new HQ will hold one of the most innovative nutritional research 01 & development laboratory in Europe R&D ▪ Exclusive lab models for the simulation of digestion and uptake of nutrients ▪ Increased prototipes in vitro scanning capabilities 03 02 ▪ High
Slide 20: Estimated Revenues Range in Five Years Time
20 ESTIMATED REVENUES RANGE IN FIVE YEARS TIME SPAIN 5-10M€ R&D N.P. AKERN 10-25M€ USA 30-40M€ CHINA 3-10M€ CETILAR® NUTRITION 5-8M€
Slide 21: Estimated Sales Development
21 ESTIMATED SALES DEVELOPMENT
Slide 22: Estimated Profitability Development
22 ESTIMATED PROFITABILITY DEVELOPMENT
Slide 23: Pharmanutra
MPHARMANUTRA